NCI Director Harold Varmus addressed a joint meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board Dec. 2, updating them on his proposed bypass budget for the institute, changes in Congressional leadership, and NCI and NIH grant policy.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
